About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate ...

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return potential and a growing 3.5% dividend.

Novartis forecasts further profit and sales growth this year after beating analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart drug Entresto.

(Bloomberg) -- Novartis AG’s Sandoz family is poised to sell a roughly 1.2% stake in the Swiss pharmaceutical group.

Novartis will acquire Anthos Therapeutics for ... Anthos is developing abelacimab, a late-stage medicine to prevent stroke and systemic embolism in patients with atrial fibrillation, a type ...

Health Canada has approved Novartis Canada’s Fabhalta (iptacopan capsules) as the first oral monotherapy to treat adults with PNH.

Novartis didn’t have the best experience ... “Our thinking is, can we develop a medicine that’s better than the current standard of care in atopic dermatitis and in some of the relevant ...

Novartis Indias NEST competition culminates in a showcase of innovative healthcare solutions, highlighting the talent of ...

Novartis AG’s Sandoz family sold a roughly 1.2% stake in the Swiss pharmaceutical group for 2.6 billion Swiss francs ($2.9 ...